IASIS PHARMA PARTICIPATION in the 20th PAN-HELLENIC SCIENTIFIC EVENT of the PROFESSIONAL ASSOCIATION OF GREEK GASTROENTEROLOGISTS (EPEGE)

27/10/2023|All articles, Press Room, Scientific conferences|

20 – 22/10/2023 Hotel Divani Caravel, Athens IASIS PHARMA participated in the “20th PAN-HELLENIC SCIENTIFIC EVENT of the PROFESSIONAL ASSOCIATION OF GREEK GASTROENTEROLOGISTS (EPEGE)” which held on October 20-22, 2023, at Divani Caravel Hotel in Athens. The purpose of this year's educational meeting was to inform about the latest scientific data, in the prevention and [...]

IASIS PHARMA PARTICIPATION IN THE: “44th PANHELLENIC CONGRESS OF CARDIOLOGY ”

20/10/2023|All articles, Company news, Press Room, Scientific conferences|

12 – 14/10/2023 Thessaloniki Concert Hall IASIS PHARMA participated in the “44th PANHELLENIC CONGRESS OF CARDIOLOGY” which held on October 12-14, 2023, at Thessaloniki Concert Hall. The conference was organized by the Hellenic Society of Cardiology (HSC). The Panhellenic Congress of Cardiology has established among Cardiologists and the Pharmaceutical Industry, as the Scientific Conference par [...]

NEW PRODUCT LAUNCH: Qpain®

16/10/2023|All articles, Product launches|

Qpain® is a new topical anti-inflammatory cutaneous solution, containing diclofenac sodium 1.5% w/w, indicated for the symptomatic relief of pain associated with osteoarthritis in superficial joints, including the knee. – Qpain® contains DMSO which enhances the absorption of diclofenac from the skin and reaches the focus of pain and inflammation directly. Ideal for those who cannot [...]

PRESS RELEASE: “90 years of PANHELLENIC ASSOCIATION OF PHARMACEUTICAL INDUSTRIES (PEF)”

06/10/2023|All articles, Company news, Press Room|

26.09.2023, Divani Caravel Hotel Athens Greece The Pharmaceutical Industry in Greece has completed 90 years since its foundation in 1933 as the Union of Pharmaceutical Laboratories which evolved into the Panhellenic Association of the Pharmaceutical Industry (P.E.F.). On Tuesday, 26.09.23, at a brilliant anniversary event at the "Divani Caravel" hotel, Panhellenic Association of Pharmaceutical Industries [...]

IASIS PHARMA participation in the “Developments in Dermatology & Venereology 2023”

02/10/2023|All articles, Company news, Press Room, Scientific conferences|

22 – 24/09/2023 Hermes Hotel, ERMOUPOLIS, SYROS ISLAND IASIS PHARMA participated in the "Developments in Dermatology & Venereology 2023" conference which held on September 22-24 2023, at the Hermes Hotel in Syros Island. The conference was organized by the Hellenic College of Dermatology-Venereology with the scientific support of the 2nd Clinic of Venereology and Skin [...]

IASIS PHARMA participation in the 6th Panhellenic Conference of S.S.D.A.D.

22/09/2023|All articles, Press Room, Scientific conferences|

Grecotel Filoxenia, Kalamata, 14-17/09/2023 During 14-17/09/2023, at Grecotel Filoxenia/KALAMATA, the Society for the Study of Dermatovenereologic and Allergic Diseases (S.S.D.A.D.) organized the 6th Panhellenic Conference “Dermatological diseases: Past, present and future”.  Dermatologists from all over Greece who attended the Conference had the chance to visit IASIS PHARMA exhibition stand and received information about IASIS major Dermatological products: Isotroin®/Isotretinoin (in the new & [...]

IASIS PHARMA PARTICIPATION AT THE 10th CONFERENCE “ATTICA DERMATOLOGY DAYS”

10/07/2023|All articles, Press Room, Scientific conferences|

Divani Caravel, Athens, 09-11/06/2023 IASIS PHARMA participated in the dermatological conference "ATTICA DERMATOLOGY DAYS", which was held on June 09-11, 2023, at the Divani Caravel hotel /Athens. The conference, which organized by the Hellenic College of Dermatology-Venereology, with the scientific support of the 2nd Clinic of Dermatology and Venereal Diseases EKPA, mainly concerned at the central [...]

NEW PRODUCT LAUNCHING: Nitrofurantoin/IASIS® oral susp. – 1st Choice, Prevention & Treatment of UTIs

29/06/2023|All articles, Press Room, Product launches|

IASIS PHARMA is pleased to announce the Nitrofurantoin/IASIS oral susp. launching in the oral suspension formulation. This Innovative Pharmaceutical Form is a global market leader. This dosage form is Research and Development by IASIS PHARMA HELLAS S.A. Each 5ml of oral suspension Nitrofurantoin/IASIS oral susp. contains 25mg of Nitrofurantoin monohydrate which, according to international literature, [...]

INAUGURATION OF THE MASTIC RESEARCH CENTER (M.R.C.)

23/06/2023|All articles, Exploiting the gifts of Greek nature, Horizon 2020, Press Room, Research & development, Research and development projects|

On Saturday, April 29th 2023, the Mastic Research Center (M.R.C.) opening was held in Kallimasia of Chios. Many people was present such as from the medical, pharmaceutical, business, political and academic field, as well as the mastic producers and guests. This project will be a reliable body that will coordinate academic interests and scientific research [...]

IASIS PHARMA PARTICIPATION IN THE 21st PANHELLENIC DIABETES CONGRESS

27/03/2023|All articles, Press Room, Scientific conferences|

Divani Caravel Hotel, Athens, 8-11/03/2023 IASIS PHARMA participated in the 21st National Diabetes Congress, showing its active interest in Diabetes Mellitus disease, promoting cornerstone pharmaceutical products for type 2 diabetes. Moreover, IASIS PHARMA is about to invest significantly in T2DM in the near future, launching more than 4 original products. The conference took place on [...]

Load More Posts